Even the goal of strict glycemic control was reached, some glucose-lowering agents such as rosiglitazone and saxagliptin were observed to increase the risk of heart failure (HF) (Savarese et al., 2021), while glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been demonstrated to be protective for cardiorenal dysfunction (Brown et al., 2021; Li et al., 2021). Here, SLC5A2 is linked to heart failure.